Decay of HIV Type 1 DNA and Development of Drug-Resistant Mutants in Patients with Primary HIV Type 1 Infection Receiving Highly Active Antiretroviral Therapy

作者: Elisabetta Riva , Mauro Pistello , Pasquale Narciso , Gianpiero D'Offizi , Patrizia Isola

DOI: 10.1089/088922201753342004

关键词:

摘要: The present study was aimed at describing the effect of highly active antiretroviral therapy (HAART) in 10 patients with primary HIV infection (PHI). Clearance rates RNA and DNA peripheral blood as well preexistence emergence drug-resistant strains were determined over 52 weeks treatment. data indicate that HAART is able to induce a suppression plasma viral load together significant decrease, but not suppression, mononuclear cell-associated proviral PHI subjects. Analysis revealed three patients, showing complete virologic response, developed mutations pol gene, thus suggesting persistent residual virus replication exists despite sustained viremia.

参考文章(22)
Sabine Yerly, Laurent Kaiser, Thomas V Perneger, Richard W Cone, Milos Opravil, Jean-Philippe Chave, Hansjakob Furrer, Bernard Hirschel, Luc Perrin, Swiss HIV Cohort Study, Time of initiation of antiretroviral therapy: impact on Hiv-1 viraemia AIDS. ,vol. 14, pp. 243- 249 ,(2000) , 10.1097/00002030-200002180-00006
C. Pedersen, B. O. Lindhardt, B. L. Jensen, E. Lauritzen, J. Gerstoft, E. Dickmeiss, J. Gaub, E. Scheibel, T. Karlsmark, Clinical course of primary HIV infection: consequences for subsequent course of infection. BMJ. ,vol. 299, pp. 154- 157 ,(1989) , 10.1136/BMJ.299.6692.154
Sabine Yerly, Thomas V. Perneger, Samir Vora, Bernard Hirschel, Luc Perrin, Decay of cell-associated HIV-1 DNA correlates with residual replication in patients treated during acute HIV-1 infection. AIDS. ,vol. 14, pp. 2805- 2812 ,(2000) , 10.1097/00002030-200012220-00001
Ferdinando Dianzani, Guido Antonelli, Fernando Aiuti, Ombretta Turriziani, Elisabetta Riva, Maria R Capobianchi, Franco Pandolfi, Gianpiero D’Offizi, IRHAN Study Group, The number of HIV DNA-infected mononuclear cells is reduced under HAART plus recombinant IL-2 Antiviral Research. ,vol. 45, pp. 95- 99 ,(2000) , 10.1016/S0166-3542(99)00080-7
Isabelle Garrigue, Isabelle Pellegrin, Bruno Hoen, Béatrice Dumon, Martine Harzic, Marie-Hélène Schrive, Daniel Séréni, Hervé Fleury, Cell-associated HIV-1-DNA quantitation after highly active antiretroviral therapy-treated primary infection in patients with persistently undetectable plasma HIV-1 RNA. AIDS. ,vol. 14, pp. 2851- 2855 ,(2000) , 10.1097/00002030-200012220-00006
Ireneus P.M. Keet, Pieta Krijnen, Maarten Koot, Joep M.A. Lange, Frank Miedema, Jaap Goudsmit, Roel A. Coutinho, Predictors of Rapid Progression to AIDS in HIV-1 Seroconverters AIDS. ,vol. 7, pp. 51- 57 ,(1993) , 10.1097/00002030-199301000-00008
Mauro Pistello, Antonietta Morrica, Fabrizio Maggi, Maria Linda Vatteroni, Giulia Freer, Claudia Fornai, Francesca Casula, Santino Marchi, Pietro Ciccorossi, Paolo Rovero, Mauro Bendinelli, TT virus levels in the plasma of infected individuals with different hepatic and extrahepatic pathology. Journal of Medical Virology. ,vol. 63, pp. 189- 195 ,(2001) , 10.1002/1096-9071(20000201)63:2<189::AID-JMV1014>3.0.CO;2-H
Madeleine A.E. von Sydow, Louise Evans, Orjan Strannegard, Ming Li Tsang, Stefan Lindback, David A. Cooper, Brett Tindall, Hans Gaines, Allison Imrie, Zidovudine in the management of primary HIV-1 infection. AIDS. ,vol. 5, pp. 477- 484 ,(1991) , 10.1097/00002030-199105000-00001
Linqi Zhang, Bharat Ramratnam, Klara Tenner-Racz, Yuxian He, Mika Vesanen, Sharon Lewin, Andrew Talal, Paul Racz, Alan S. Perelson, Bette T. Korber, Martin Markowitz, Yong Guo, Margarita Duran, Arlene Hurley, John Tsay, Yu-Ching Huang, Chia-Ching Wang, David D. Ho, Quantifying residual HIV-1 replication in patients receiving combination antiretroviral therapy. The New England Journal of Medicine. ,vol. 340, pp. 1605- 1613 ,(1999) , 10.1056/NEJM199905273402101
Cécile Poggi, Nérina Profizi, Abdelaziz Djediouane, Lionel Chollet, Gilles Hittinger, Alain Lafeuillade, Long-term evaluation of triple nucleoside therapy administered from primary HIV-1 infection. AIDS. ,vol. 13, pp. 1213- 1220 ,(1999) , 10.1097/00002030-199907090-00010